GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection.
Sign Up to like & getrecommendations! Published in 2020 at "Advances in experimental medicine and biology"
DOI: 10.1007/5584_2020_494
Abstract: The risk of cardiovascular disease (CVD) (myocardial infarction, stroke, peripheral vascular disease) is twice in type 2 diabetes (T2D) patients compared to non-diabetic subjects. Furthermore, cardiovascular disease (CV) is the leading cause of death in… read more here.
Keywords: type diabetes; treatment; receptor agonists; cardiovascular protection ... See more keywords
Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage
Sign Up to like & getrecommendations! Published in 2021 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehab724.2284
Abstract: The nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone and SGLT2 inhibitors have demonstrated clinical benefits in HFrEF and CKD patients with T2D. Cardiovascular protection with finerenone and the SGLT2 inhibitor empagliflozin in combination in hypertensive cardiorenal… read more here.
Keywords: combination; cardiovascular protection; finerenone sglt2; finerenone ... See more keywords
Cardiovascular Protection Associated With Cilostazol, Colchicine, and Target of Rapamycin Inhibitors
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cardiovascular Pharmacology"
DOI: 10.1097/fjc.0000000000001276
Abstract: Abstract: An alteration in extracellular matrix (ECM) production by vascular smooth muscle cells is a crucial event in the pathogenesis of vascular diseases such as aging-related, atherosclerosis and allograft vasculopathy. The human target of rapamycin… read more here.
Keywords: cardiovascular protection; target rapamycin; disease; cilostazol colchicine ... See more keywords
Mechanisms of cardiovascular protection of non-insulin antidiabetic medications
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes mellitus"
DOI: 10.14341/dm9816
Abstract: Patients with type 2 diabetes mellitus die most frequently from cardiovascular disease (CVD). Metabolic control is a cornerstone of both primary and secondary prevention of CVD: its important is two-fold since the normalization of HbA1c… read more here.
Keywords: protection; mechanisms cardiovascular; cardiovascular protection; diabetes mellitus ... See more keywords
A role for misaligned gene expression of fetal gene program in the loss of female-specific cardiovascular protection in young obese and diabetic females
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2023.1108449
Abstract: Healthy, premenopausal women have the advantage of female-specific cardiovascular protection compared to age-matched healthy men. However, pathologies such as obesity and Type 2 diabetes mellitus (T2DM) cause losing of this female-specific cardiovascular protection in young,… read more here.
Keywords: protection young; cardiovascular protection; female specific; specific cardiovascular ... See more keywords
Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update
Sign Up to like & getrecommendations! Published in 2023 at "Molecules"
DOI: 10.3390/molecules28031369
Abstract: Angiotensin II (Ang II), a peptide hormone generated as part of the renin–angiotensin system, has been implicated in the pathophysiology of many cardiovascular diseases such as peripheral artery disease, heart failure, hypertension, coronary artery disease… read more here.
Keywords: protection long; glp receptor; cardiovascular protection;